Solid Tumors

Independent review of anticancer drugs reports initial clinical successes

Published in Gene Therapy Weekly, May 15th, 2003

An article published in the April issue of Seminars in Cancer Biology reviews Introgen Therapeutics' (INGN) products Advexin and INGN 241, among others, and reports that successes in clinical trials have been achieved with Advexin and describes phase I studies with INGN 241 as promising.

Advexin is Introgen's p53 gene based cancer therapeutic being evaluated in two phase III studies, five phase II clinical studies, and numerous phase I studies totaling studies in 10 cancers. INGN 241, an mda-7 gene based cancer therapeutic, is being evaluated in phase I and phase II trials for various solid tumors. Both products are covered by multiple issued and pending patents...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry